Part Two: Trust, Technology & the Future of Compounding
CurifyLabs customer T.W. Taylor featured on podcast that explores "Trust, Technology and the Future of Compounding"
How can compounding pharmacies embrace new technology while keeping quality and patient care at the center of their work? Featured guests Tenille Davis, Chief Advocacy Officer for the Alliance for Pharmacy Compounding, and T.W. Taylor, Owner of Williamsburg Drug Co., join Pharmacy Podcast Network host Todd Eury to explore this question in the CurifyLabs Podcast Series, “Trust, Technology & the Future of Compounding.”
Together, they discuss the state of the industry, opportunities for independent pharmacies and how pharmacists can evaluate emerging technologies as automation becomes increasingly integrated into their workflows.
The discussion examines what determines compounded dose quality, including validation, documentation, repeatability, traceability, formulation homogeneity, dispensing accuracy and pharmacist oversight. Throughout the conversation, the emphasis is on looking beyond marketing claims to understand the evidence supporting a technology’s performance.
In “Fact Check: Compounding Edition,” Eury and Davis address common misconceptions, including whether mass uniformity equals content uniformity and whether greater automation automatically means greater quality.
The central message is clear: the future of compounding depends on bringing technology, evidence, compliance, and pharmacist expertise together to advance personalized patient care responsibly.
Listen to “Trust, Technology & the Future of Compounding” to hear the full conversation.
